(Q42554661)

2 November 2017

title

Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice (English)

1 reference

Mycobacterium tuberculosis

2 November 2017

main subject

1 reference

1 reference

Reddy MV

1

1 reference

2 November 2017

Luna-Herrera J

series ordinal

2

1 reference

2 November 2017

Daneluzzi D

series ordinal

3

1 reference

2 November 2017

Gangadharam PR

series ordinal

4

1 reference

2 November 2017

publication date

1 April 1996

1 reference

Tubercle and lung disease

2 November 2017

published in

1 reference

2 November 2017

volume

77

1 reference

2 November 2017

issue

2

1 reference

2 November 2017

page(s)

154-159

1 reference

In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins

2 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0962-8479%2896%2990030-1

7 January 2021

Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0962-8479%2896%2990030-1

7 January 2021

Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0962-8479%2896%2990030-1

7 January 2021

In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS0962-8479%2896%2990030-1

7 January 2021

Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS0962-8479%2896%2990030-1

7 January 2021

In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains

1 reference

https://api.crossref.org/works/10.1016%2FS0962-8479%2896%2990030-1

7 January 2021

The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0962-8479%2896%2990030-1

7 January 2021

Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli.

1 reference

https://api.crossref.org/works/10.1016%2FS0962-8479%2896%2990030-1

7 January 2021

10.1016/S0962-8479(96)90030-1

Identifiers

DOI

1 reference

2 November 2017

1 reference